Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 46 |
| INN | Reslizumab |
| Status | Approved |
| Drug code(s) | CEP-38072, CDP-835, SCH-55700 |
| Brand name | Cinquil |
| mAb sequence source | mAb humanized |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG4 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | IL-5 |
| Indications of clinical studies | Eosinophilic Asthma, Eosinophilic Esophagitis |
| Primary therapeutic area | Immune-mediated / inflammatory disorders |
| Most advanced stage of development (global) | Approved EU, US, Australia |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | July 02, 1997 |
| Start of Phase 2 | |
| Start of Phase 3 | February 15, 2008 |
| Date BLA/NDA submitted to FDA | March 30, 2015 |
| Year of first approval (global) | 2016 |
| Date of first US approval | March 23, 2016 |
| INN, US product name | Reslizumab |
| US or EU approved indications | Astham (Add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype) |
| Company | UCB |
| Licensee/Partner | Teva, Schering-Plough |
| Comments about company or candidate | Positive Phase III Results for Reslizumab Reducing Asthma Exacerbations released in Sep 2014 Partner Teva acquired Cephalon in 2011; Cephalon acquired Ception in 2009. |
| Full address of company | Allée de la Recherche, 60 1070 Brussels Belgium Europe Belgium https://www.ucb.com/contact |
Wild-type hinge
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |